ABVC Biopharma completes BioKey Cayman spinoff, distributes 15% stake to shareholders

Reuters2026/08/27 12:32

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

ABVC BioPharma completed a partial separation of BioKey Cayman via a pro rata dividend of about 15% of its ordinary shares.
Stockholders of record on July 24, 2026 received 0.169464 BioKey Cayman share per ABVC share; distribution took effect Aug. 21, 2026.
Total shares distributed: 4,500,390; ABVC retained about 85% control, leaving BioKey Cayman no longer a wholly owned subsidiary.
BioKey Cayman became a separate Exchange Act reporting company on June 25, 2026; it plans to seek OTC Markets quotation.
Separation terms include transitional services, tax, employee, and other ongoing relationship agreements, including mutual releases and indemnities.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ABVC Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-094152), on August 27, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

ABVC Biopharma completes BioKey Cayman spinoff, distributes 15% stake to shareholders

You may also like

Crypto prices